Macrogen Q1 2026: Revenue Growth, Operating Loss Reduction, Credit Rating Upgrade

Q1 2026 consolidated revenue KRW 45.3 billion (up 10.6% YoY from KRW 41.0 billion)
Consolidated operating loss KRW 0.51 billion (significant improvement from KRW 3.05 billion loss in prior year)
Consolidated net loss KRW 0.83 billion (controlling interest net loss KRW 0.44 billion)
Credit rating upgraded from BB to BBB+ (Korea Rating & Data, April 2026)
FY2025 dividend KRW 5.42 billion (KRW 500 per share) paid in April 2026
Under contract for national bio big data project worth KRW 17.5 billion
Completion of Songdo Global Genome Center; Gentok service launched on Samsung Health
Consolidated debt-to-equity ratio 120%, short-term borrowings KRW 61 billion, cash & equivalents KRW 54.2 billion
No share buyback or cancellation plans